RARE DISEASE PSI’s overall therapeutic expertise includes the management of pharmaceutical trials in a variety of rare disease indications. Treating rare diseases is one of the most rapidly expanding areas in clinical research yet there is no consensus on what constitutes an ideal approach. PSI’s methodology involves applying the lessons learned from pediatric and oncology drug development to rare disease programs. That means we can speak with you about project planning, protocol realities, logistical possibilities and the execution of all aspects of your clinical trial. Conducting a rare disease trial comes with inherent challenges that arise from two elements; a sparse patient population and a wide geographical spread. The challenges cascade from there: assess the clinical reality of the protocol, identify the investigators, determine an enrollment rate and calculate an overall timeline based on various regulatory requirements in each country. When the cost per patient is considered, it becomes readily apparent that conducting thorough feasibility is a key critical success factor for orphan drug trials. PSI’s dedicated, global Feasibility Department, comprised of medical specialists, laboratory experts, imaging specialists, logisticians and regulatory experts, has conducted feasibility across a wide range of rare diseases. Each protocol has received a thorough medical, clinical, logistical and regulatory assessment. When we apply this process to your study and combine it with our knowledge of the nuances and complexities associated with conducting orphan drug trials, we can provide recommendations for the best choice of sites, geography and realistic timelines for your study. These elements allow our clients to determine the true price of a study.
For more information about PSI, please visit our website WWW.PSI-CRO.COM or reach us at CONTACT@PSI-CRO.COM
It has been a great pleasure to work with each of you. I truly admire your ability to work so effectively with the sites- I’m sure our study would not have been such a great success if it weren’t for the relationships you have built with our investigators. Clinical Trial Manger, USA